Moksoniteks Tab n / a film about 0.2mg 28 pc

Description

Composition
Active substance:
1 tablet contains: 0.2 mg of moxonidine / 0.3 mg / 0.4 mg.
Excipients:
Lactose monohydrate, povidone K-25, crospovidone, magnesium stearate. composition of the film coating: Opadry Y-1-7000 (titanium dioxide, hypromellose, macrogol 400), red iron oxide colorant.
Description:
Dosage 0.2 mg: Round biconvex tablets, film-coated light pink color.
Dosage 0.3 mg: Round biconvex tablets, film-coated pink.
Dosage 0.4 mg: Round biconvex tablets, film-coated dark pink.
Product form:
Tablets, film-coated 0.2 mg; 0.3 mg; 0.4 mg.
At 7, 10 or 14 tablets per blister.
1, 2, 3, 4 and 5 blisters together with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to moxonidine or any other component of the formulation; inherited lactose intolerance, lactase deficiency or glucose-galactose malabsorption; expressed cardiac rhythm (bradycardia (less than 50 beats / min alone), sick sinus syndrome and sinoatrial block, atrioventricular block II and III degree); Chronic heart failure (III-IV NYHA functional class classifying); severe renal failure (creatinine clearance
Dosage
0.2 mg
Indications
Arterial hypertension.
Interaction with other drugs
The combined use of Moxonidine with other antihypertensives leads to additive effect. Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents, and therefore is not suitable for taking them together with moxonidine.
Moxonidine may enhance the sedative effect of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics.
Moxonidine is able to moderately improve cognitive impairment in patients receiving lorazepam.
Moxonidine may enhance the sedative effect of benzodiazepines during their simultaneous use.
Moxonidine is obtained by tubular secretion, so it is not possible interaction with other drugs that can be output by tubular secretion.
Overdose
Symptoms: headache, pronounced decrease in blood pressure, bradycardia, palpitations, weakness, drowsiness, dry mouth mucosa, rarely – vomiting, epigastric pain. Potentially possible paradoxical hypertension and hyperglycemia.
Treatment: symptomatic. No specific antidote.
In marked decrease in blood pressure should restore circulating blood volume due to the introduction of the liquid.
Alpha-adrenoreceptor antagonists can reduce or eliminate transient hypertension with Moxonidine overdose.
pharmachologic effect
Pharmacological group:
Centrally acting antihypertensive agent.
Pharmacodynamics:
Selective imidazoline receptor agonist is responsible for the control of reflex sympathetic nervous system (localized in the ventro-lateral medulla). Slightly communicates with the central alpha2-adrenoceptors, reduced systolic and diastolic blood pressure (BP) and after a single long-term use.
With prolonged use reduces left ventricular hypertrophy, myocardial fibrosis eliminates the symptoms, mikroarteriopatii normalizes capillary blood supply of the myocardium, reducing the total peripheral vascular resistance, pulmonary vascular resistance, while the cardiac output and heart rate (HR) were not significantly changed. The treatment reduces the activity of norepinephrine and epinephrine, renin, angiotensin II at rest and during exercise, the atrial natriuretic peptide (under a load) and aldosterone blood plasma. Decreases Resistance to insulin by 21% compared to placebo in patients with obesity and insulin-resistant patients with moderate hypertension, it stimulates the release of growth hormone. It has no effect on glucose metabolism and lipid.
Pharmacokinetics:
Suction. After ingestion rapidly and almost completely absorbed from the gastrointestinal tract (90%). Admission to the amount of food absorption is not affected. Maximum plasma concentration (Cmax) is reached after 30-180 minutes and after oral administration is 1-3 ng / ml. The interval between Cmax and achieving a marked reduction of blood pressure alone varies an average of 10%, with a load – by 7.7%. Duration -. The bioavailability of more than 12 hours after a single application of 88% inside, indicating no significant effect of “primary” passing through the liver.
Distribution. It penetrates the blood-brain barrier. Not accumulates long-term use.
The volume of distribution – 1,4-3 l / kg. Communication with the plasma proteins 7%.
Metabolism. 10-20% moxonidine metabolized to form 4,5-degidromoksonidina and aminometanamidinovogo derivative.
Withdrawal. The half-life (T1 / 2) is about 2-3 h during the first 24 hours, kidneys displayed more than 90% (50-75% – unchanged, 20% – as metabolites). And about 1% – in the bile. Moxonidine in small amounts appear in hemodialysis.
Special patient groups
Elderly age?
No significant differences in pharmacokinetics in younger patients and elderly patients were found. Correction dose is not required under normal renal function.
Renal function
In patients with moderate (creatinine clearance (CC) of 30-60 ml / min) and heavy (CC
Pregnancy and breast-feeding
Reliable trials of moxonidine in pregnant women have been conducted. Animal studies have shown embryotoxic effect. Clinical data on the negative impact on the course of pregnancy there. However, it should use the drug Moksoniteks pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus.
Moxonidine passes into breast milk, women during treatment is recommended to stop breast-feeding or stop the drug.
Conditions of supply of pharmacies
On prescription.
side effects
According to the World Health Organization (WHO) side effects are classified according to their rate of development as follows: common (> 1/100,
special instructions
During treatment requires regular monitoring of blood pressure, heart rate and ECG. If necessary, cancel the concomitant beta-blockers and drug Moksoniteks first override beta-blockers, and only after a few days of preparation Moksoniteks.
There is currently no evidence that discontinuation of Moksoniteks drug leads to increased blood pressure. But we should not abruptly stop the drug use Moksoniteks. Elderly patients may be at increased risk for cardiovascular events due to the use of antihypertensive drugs, so drug therapy Moksoniteks should start with the lowest dose.
Moksoniteks effect of the drug on the ability to drive vehicles or operate machinery has not been studied. However, taking into account the possibility of dizziness, drowsiness, patients should be careful during the occupation of potentially hazardous activities that require attention, such as driving a vehicle or control technique, which requires high concentration of attention.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children!.
Dosing and Administration
Moksoniteks appointed inwardly regardless of food intake, drinking plenty of fluids. the dose regimen selected individually.
Unless otherwise Moksoniteks prescriptions should be administered in the following doses: as an initial dose of 0.2 mg of the drug administered in the morning. When insufficient therapeutic effect, the dose 3 weeks later increased to 0.4 mg / day in single or 2 divided doses. The maximum daily dose – 0.6 mg, the maximum single dose of 0.4 mg.
In patients with moderately severe lesions of the kidney function (creatinine clearance 30 – 60 ml / min) single dose should not exceed 0.2 mg and a maximum daily dose – 0.4 mg.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist